LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
=== Filtration === Chitosan can be used in hydrology as a part of a filtration process. Chitosan causes the fine sediment particles to bind together, and is subsequently removed with the sediment during sand filtration. It also removes heavy minerals, dyes, and oils from the water. As an additive in water filtration, chitosan combined with sand filtration removes up to 99% of turbidity. Chitosan is among the biological adsorbents used for heavy metals removal without negative environmental impacts. Chitosan is used to flocculate algal blooms in ponds and lakes due to the cyanobacteria possessing a negatively-charged cell wall which binds to the cationic chitosan polymer. In combination with bentonite, gelatin, silica gel, isinglass, or other fining agents, it is used to clarify wine, mead, and beer. Added late in the brewing process, chitosan improves flocculation, and removes yeast cells, fruit particles, and other detritus that cause hazy wine.
=== New generation fuel === The aim of Guy Reinaud's project is to reply to the needs, in renewable domestic energy, of a population of 2 billion individuals living in the tropical regions of Africa, Latin America and Asia, and at the same time fighting against deforestation and climatic changes. The proposed solution is biomass charcoal as a source of renewable energy - patented and developed by Pro-Natura International. Biomass charcoal produces domestic energy from non-upgraded biomass, other than wood, in particular agricultural residues non-consumed by animals. By reducing the dependence on wood, biomass charcoal protects forests and as a consequence fights against desertification. Moreover, the energy produced by biomass charcoal is equal to that of wood charcoal for a sales price per kilo 50% cheaper.
== Additional sources == Birkhead T, Wimpenny J; Montgomerie B (2014). Ten Thousand Birds: Ornithology since Darwin. Princeton University Press. ISBN 978-0-691-15197-7. Chansigaud, Valerie (2009). History of Ornithology. London: New Holland Publishers. ISBN 978-1-84773-433-4. Gurney, John Henry (1921). "Early annals of ornithology". Nature. 108 (2713): 268. Bibcode:1921Natur.108..268.. doi:10.1038/108268a0. hdl:2027/coo.31924090299532. S2CID 4033666. Retrieved 19 November 2010. Newton, Alfred (1884). Ornithology. [S.l. : s.n.(Reprinted from the 1884 Encyclopædia Britannica) Podulka, Sandy; Eckhardt, Marie; Otis, Daniel (2001). "Birds and Humans: A Historical Perspective". In Podulka, Sandy; Rohrbaugh, Ronald W.; Bonney, Rick (eds.). Handbook of Bird Biology (2nd ed.). Ithaca, NY: Cornell Lab of Ornithology. pp. H1–H42. ISBN 978-0-938027-62-1. Walters, Michael (2005). A Concise History of Ornithology. New Haven, CT: Yale University Press. ISBN 978-1-84773-433-4.
Sources: en.wikipedia.org
=== Mechanical engineering === When a periodic force is applied to a mechanical system, it will typically reach a steady state after going through some transient behavior. This is often observed in vibrating systems, such as a clock pendulum, but can happen with any type of stable or semi-stable dynamic system. The length of the transient state will depend on the initial conditions of the system. Given certain initial conditions, a system may be in steady state from the beginning.
The interpretation of the law of definite proportions in terms of the atomic theory of matter implied that the masses of atoms of various elements had definite ratios that depended on the elements. While the actual masses were unknown, the relative masses could be deduced from that law. In 1803 John Dalton proposed to use the (still unknown) atomic mass of the lightest atom, hydrogen, as the natural unit of atomic mass. This was the basis of the atomic weight scale. For technical reasons, in 1898, chemist Wilhelm Ostwald and others proposed to redefine the unit of atomic mass as 1/16 the mass of an oxygen atom. That proposal was formally adopted by the International Committee on Atomic Weights (ICAW) in 1903. That was approximately the mass of one hydrogen atom, but oxygen was more amenable to experimental determination. This suggestion was made before the discovery of isotopes in 1912. Physicist Jean Perrin had adopted the same definition in 1909 during his experiments to determine the atomic masses and the Avogadro constant. This definition remained unchanged until 1961. Perrin also defined the "mole" as an amount of a compound that contained as many molecules as 32 grams of oxygen (O2). He called that number the Avogadro number in honor of physicist Amedeo Avogadro.
== Medical uses == Lumateperone is indicated for the treatment of schizophrenia in adults; and depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate.
== Helicity (polarization) of neutrinos, electrons and positrons emitted in beta decay == After the discovery of parity non-conservation (see § History), it was found that, in beta decay, electrons are emitted mostly with negative helicity, i.e., they move, naively speaking, like left-handed screws driven into a material (they have negative longitudinal polarization). Conversely, positrons have mostly positive helicity, i.e., they move like right-handed screws. Neutrinos (emitted in positron decay) have negative helicity, while antineutrinos (emitted in electron decay) have positive helicity. The higher the velocity (energy) of the particles, the higher their helicity polarization; this reflects the absolute chirality selection in W boson decay.
Sources: en.wikipedia.org
== History == The study of lichen acids related to protolichesterinic acid began in 1845, when Schnedermann and Wilhelm Knop isolated lichesterinic acid from Cetraria islandica var. vulgaris. They determined it had a melting point around 120 °C (248 °F) and established its composition as C19H32O4. Further research by H. Sinnhold in 1898 worked with pure lichesterinic acid (melting point 124.5–125 °C). In 1900, Oswald Hesse isolated three varieties (α-, β-, and γ-) of lichesterinic acid from Cetraria islandica, with specific rotations of +27.9°, +27.9°, and +16° respectively. Protolichesterinic acid was first isolated at the beginning of the 20th century by Friedrich Wilhelm Zopf from the lichen Cetraria cucullata (now known as Cladocetraria cucullata). Zopf initially found it alongside usnic acid and noticed that while it showed similarities to lichesterinic acid in some properties, it differed significantly in melting point and other characteristics. The compound was named "protolichesterinic acid" to reflect its close relationship to lichesterinic acid, and the discovery was published in Liebigs Annalen in 1902. After obtaining it in crystalline form through extraction with ether and recrystallization from warm benzol, Zopf determined that protolichesterinic acid formed thin, rhombic, pearly plates that melted at 103–104 °C (217–219 °F), lower than lichesterinic acid's melting point of 124–125 °C (255–257 °F).
On July 6, 2025, furious that their Acting Grand Master had been arrested, dozens of members of the High Chamber held a large protest in front of the National Masonic Temple in rejection of Filema Duarte's authority to call any session of the High Chamber. The session had been scheduled to occur later that day. However, when they tried to enter the building, the Tyler was joined by three Freemasons who sided with Filema Duarte – Jesús Martínez Frómeta, Raúl Pérez Martín and Rolando Céspedes Mena – who refused the protesters entry to the building. The two sides pushed and shoved. The protestors cried and shouted for Filema Duarte to exit the building, and he did come down to try and meet with them. But Former Grand Master Ernesto Zamora Fernández then, in a video which appeared on Zamora Fernández's Facebook profile, was seen leading a chant of "Out, traitor! Get out!" Filema Duarte retreated back into his office, with the Freemasons still shouting at him that he was a traitor to the Brotherhood and a puppet of the Cuban government. Filema Duarte issued a statement that he had cancelled the session of the High Chamber, in which he also stated that he would not be stepping aside as Grand Master. On Facebook, Zamora Fernández wrote: "This is the face of the dictatorship dressed as the Grand Master of the Cuban Masons, his name: Maikel Filema. He is worse than Agent Collera Vento. Dismissed by the Masons, he clings to power with the support of the government... Your betrayal, your lack of civility, your lack of morality, your ignorance. Your baseness, your lack of ethics.
Investigation about the temporal and magnitude of inflammatory response in the vocal cords may benefit for elucidating subsequent pathological events in vocal fold wounding, which is good for clinician to develop therapeutic targets to minimize scar formation. In the proliferative phase of vocal cord wound healing, if the production of hyaluronic acid and collagen is not balanced, which means the hyaluronic acid level is lower than normal, the fibrosis of collagen cannot be regulated. Consequently, regenerative-type wound healing turns to be the formation of scar. Scarring may lead to the deformity of vocal fold edge, the disruption of lipopolysaccharides viscosity and stiffness. Patients suffering from vocal fold scar complain about increased phonatory effort, vocal fatigue, breathlessness, and dysphonia. Vocal fold scar is one of the most challenging problems for otolaryngologists because it is hard to be diagnosed at germinal stage and the function necessity of vocal cords is delicate.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.